瑞典针对单价XBB.1.5适应性BNT162b2 mRNA加强针的体液免疫反应。 - Suppr

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.

作者信息

Marking Ulrika, Bladh Oscar, Aguilera Katherina, Yang Yiqiu, Greilert Norin Nina, Blom Kim, Hober Sophia, Klingström Jonas, Havervall Sebastian, Åberg Mikael, Sheward Daniel J, Thålin Charlotte

机构信息

Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden; Public Health Agency of Sweden, Sweden.

Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden.

出版信息

Lancet Infect Dis. 2024 Feb;24(2):e80-e81. doi: 10.1016/S1473-3099(23)00779-X. Epub 2024 Jan 5.

DOI:10.1016/S1473-3099(23)00779-X

PMID:38190833

Abstract

摘要

相似文献

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.瑞典针对单价XBB.1.5适应性BNT162b2 mRNA加强针的体液免疫反应。

Lancet Infect Dis. 2024 Feb;24(2):e80-e81. doi: 10.1016/S1473-3099(23)00779-X. Epub 2024 Jan 5.

Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.BNT162b2 XBB.1.5疫苗接种后的体液免疫和细胞免疫反应。

Lancet Infect Dis. 2024 Jan;24(1):e1-e3. doi: 10.1016/S1473-3099(23)00690-4. Epub 2023 Nov 20.

Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.BNT162b2 BA.4/5 二价 mRNA 疫苗在美国大型医疗体系中针对一系列 COVID-19 结局的有效性：一项病例对照研究。

Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25.

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines.使用科兴和国药的新冠疫苗与辉瑞 mRNA 疫苗加强针的异源和同源免疫应答比较。

Rev Soc Bras Med Trop. 2023 Jul 24;56:e00462023. doi: 10.1590/0037-8682-0046-2023. eCollection 2023.

Serum C reactive protein predicts humoral response after BNT162b2 booster administration.血清C反应蛋白可预测BNT162b2加强针接种后的体液免疫反应。

J Infect. 2022 Jul;85(1):e24-e25. doi: 10.1016/j.jinf.2022.04.015. Epub 2022 Apr 8.

Waning of humoral immunity depending on the types of COVID-19 vaccine.体液免疫的减弱取决于新冠疫苗的类型。

Infect Dis (Lond). 2023 Mar;55(3):216-220. doi: 10.1080/23744235.2023.2165707. Epub 2023 Jan 10.

Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.在一项纵向观察研究中，BNT162b2 两剂接种后医护人员的免疫反应持续存在。

Front Immunol. 2022 Mar 4;13:839922. doi: 10.3389/fimmu.2022.839922. eCollection 2022.

Decline of immune humoral response after BNT162b2 vaccine.BNT162b2疫苗接种后免疫体液反应的下降。

J Infect. 2022 Apr;84(4):e34-e35. doi: 10.1016/j.jinf.2022.02.013. Epub 2022 Feb 17.

Dynamics of the Cellular and Humoral Immune Response After BNT162b2 Messenger Ribonucleic Acid Coronavirus Disease 2019 (COVID-19) Vaccination in COVID-19-Naive Nursing Home Residents.新型冠状病毒肺炎（COVID-19）疫苗接种初免的养老院居民接种BNT162b2信使核糖核酸疫苗后细胞免疫和体液免疫反应的动态变化

J Infect Dis. 2021 Nov 22;224(10):1690-1693. doi: 10.1093/infdis/jiab458.

Humoral immune response after different SARS-CoV-2 vaccination regimens.不同 SARS-CoV-2 疫苗接种方案后的体液免疫应答。

BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x.

引用本文的文献

Subgenomic RNA and Limited Cross-Reactive Neutralising Antibodies Point to Potential Improvements in SARS-CoV-2 Clinical Handling.亚基因组RNA和有限的交叉反应性中和抗体表明SARS-CoV-2临床处理可能存在改进之处。

Int J Mol Sci. 2025 Mar 24;26(7):2948. doi: 10.3390/ijms26072948.

The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells.XBB.1.5 mRNA加强疫苗不会显著增加XBB.1.5单反应性T细胞的百分比。

Front Immunol. 2025 Mar 12;16:1513175. doi: 10.3389/fimmu.2025.1513175. eCollection 2025.

Neutralizing antibody responses to three XBB protein vaccines in older adults.老年人对三种XBB蛋白疫苗的中和抗体反应。

Signal Transduct Target Ther. 2025 Feb 3;10(1):48. doi: 10.1038/s41392-025-02132-y.

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-related Hospitalizations and Medical Encounters Among Adults in the United States.2023 - 2024含奥密克戎XBB.1.5的mRNA新冠疫苗（mRNA-1273.815）在美国成年人中预防新冠相关住院和就医的有效性

Open Forum Infect Dis. 2024 Nov 26;11(12):ofae695. doi: 10.1093/ofid/ofae695. eCollection 2024 Dec.

Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity.XBB.1.5 适应性加强疫苗接种对 SARS-CoV-2 免疫印记的影响。

NPJ Vaccines. 2024 Nov 21;9(1):231. doi: 10.1038/s41541-024-01023-7.

Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.使用联合佐剂进行异源肌内mRNA初免/鼻内蛋白加强免疫后增强的黏膜严重急性呼吸综合征冠状病毒2免疫力

Mol Ther. 2024 Dec 4;32(12):4448-4466. doi: 10.1016/j.ymthe.2024.10.016. Epub 2024 Oct 28.

Dynamic changes of neutralizing antibody and memory T cell responses six months post Omicron XBB reinfection.奥密克戎 XBB 再感染后 6 个月中和抗体和记忆 T 细胞应答的动态变化。

Front Immunol. 2024 Oct 7;15:1477721. doi: 10.3389/fimmu.2024.1477721. eCollection 2024.

Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.XBB.1.5疫苗接种在养老院居民中引发的对既往SARS-CoV-2毒株和JN.1变体的广泛免疫原性。

Geroscience. 2025 Apr;47(2):1887-1896. doi: 10.1007/s11357-024-01346-2. Epub 2024 Oct 12.

Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.人类和仓鼠血清在鉴定 SARS-CoV-2 变体（包括 JN.1）中的抗原漂移方面具有良好的相关性。

J Virol. 2024 Nov 19;98(11):e0094824. doi: 10.1128/jvi.00948-24. Epub 2024 Oct 4.

Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.XBB.1.5 mRNA 疫苗加强针接种 6 个月后仍保持强劲的 SARS-CoV-2 中和抗体。

Cell Rep Med. 2024 Sep 17;5(9):101701. doi: 10.1016/j.xcrm.2024.101701. Epub 2024 Aug 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献